Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...